EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
The efficacy of EGFR tyrosine kinase inhibitors (TKIs) varies among different EGFR mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non-small cell lung cancer (NSCLC) patients with the L858R mutation. The progression-free survival (PFS) for patients receiving TKIs as first-line therapy was longer than those who received chemotherapy (hazard ratio [HR]: 0.44, P < 0.001). Subgroup analyses showed that first-line TKI therapy resulted in longer PFS among non-smokers (HR: 0.41, P < 0.001), male (HR: 0.49, P = 0.002), female (HR: 0.39, P < 0.001), and patients with adenocarcinoma histology (HR: 0.41, P < 0.001). However, among patients with non-adenocarcinoma histology (HR: 1.11, P = 0.824) and those who used to smoke (HR: 0.55, P = 0.093), first-line TKI therapy failed to demonstrate statistically longer PFS compared to chemotherapy. Our results demonstrated that for patients with L858R mutation, first-line TKI therapy provided better survival benefits. However, among non-adenocarcinoma patients and those who used to smoke, the PFS in cohorts receiving first-line chemotherapy or TKI were not significantly different. The results of the current study will be helpful for decision-making in the treatment of patients with L858R mutation.
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Jianlin
J
Xu
Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Haitang
H
Yang
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Bo
B
Jin
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Yuqing
Y
Lou
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Yanwei
Y
Zhang
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Xueyan
X
Zhang
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Hua
H
Zhong
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Huiming
H
Wang
Central laboratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Dan
D
Wu
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Baohui
B
Han
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D004358:Drug Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D017671:Platinum Compounds / Q000627:therapeutic use; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use
D017671:Platinum Compounds; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib